N oninvasive ventilation (NIV)
is a well-recognized approach to acute respiratory failure (ARF) in adults, with a positive effect on gas exchanges and a reduced frequency of complications related to mechanical ventilation (1) (2) (3) (4) (5) (6) (7) (8) . In adults with chronic obstructive pulmonary disease, the use of NIV is recommended as a first-line intervention because it reduces mortality, the need of tracheal intubation, and the rate of complications due to the length of stay in the intensive care unit (1) (2) (3) 8) .
NIV has also been proposed as a useful therapeutic option in pediatric intensive care for the management of ARF (9 -13) . The reasons claimed for its use are based on the avoidance of endotracheal intubation, with its associated risks of local airway injury, and the reduction of nosocomial infections (1, 14, 15) .
Nevertheless, pediatric NIV therapy has only been described in case reports and uncontrolled studies (9 -13) , and there are limited data on the effects of noninvasive ventilation in pediatric patients Ͻ5 yrs of age (14) .
NIV can be delivered by means of a nasal or facial mask (3) , but it may fail in a significant number of cases because of technical problems such as gas leaks around the mask or absence of specifically trained team (3, 16) , or because of problems such as skin lesions, pain, discomfort, and claustrophobia (3, 14, 17) , which may result in loss of tolerance of the mask and lead to the use of sedative drugs to maintain positive airway pressure (3, 14) . Even with sedation, intolerance of the mask can result in NIV discontinuity; tracheal intubation is then mandatory to improve gas exchange.
Several studies have demonstrated the feasibility and effectiveness of continuous positive airway pressure (CPAP) for the treatment of respiratory distress syndrome in preterm infants by means of nasal prongs, nasopharyngeal tubes, a nasal mask, or a face mask, and with nasal cannulae (18) , but these techniques are not effective in the pediatric population.
The effectiveness of a head-hood for delivery of CPAP was previously described in preterm infants (19, 20) ; a new transparent helmet was recently tested (21) , and the device was successfully used to deliver NIV to adult patients with acute hypoxemic respiratory failure (6, 22) . In this study, we attempted to provide a better tolerated form of NIV to children Ͻ5 yrs of age by testing the use of a modified transparent helmet for delivering noninvasive CPAP in critically ill pediatric patients with hypoxemic ARF.
METHODS
Equipment. The helmet (CaStar; Starmed, Mirandola, Italy) is made of transparent, latexfree, polyvinyl chloride. The helmet is secured by a device we have called a "baby-body," which is worn under the pubic region as a pair of pants; the "baby-body" is fixed to the plastic ring (that joins the helmet to a soft collar) by two pairs of hooks, two anterior and two posterior (Fig. 1) . The size of the pediatric helmet was modified to allow a better seal at the connection and improved adherence to the neck: The small size (internal gas volume of about 7 L) is for infants Ͻ10 kg, and the large size (internal gas volume of about 9 L) is for infants Ͼ10 kg. The "baby-body" is available in three different sizes (small, medium, and large) to ensure comfort and a proper seal.
The helmet's two gas ports act as the inlet and outlet for inspiratory and expiratory gas flows; the inlet opening is connected to air and oxygen flowmeters. The outlet opening is connected to the water valve that allows CPAP level adjustment.
Since a certain level of carbon dioxide (CO 2 ) rebreathing was expected during helmet-delivered CPAP, inspiratory gas flows were set to 30 L/min (21) . Humidification of inspired gas was achieved through a cascadetype heater/humidifier and adjusted according to the tolerance and body temperature of the patient. Continuous airway pressure was ascertained by persistent water valve bubbling.
The helmet is provided with an antiasphyxia bidirectional safety valve (Fig. 2) . This valve, thanks to the membrane-system's precalibrated spring, can be opened immediately to prevent suffocation in the event that ventilation gas delivery stops. The device is automatically activated when the pressure inside the hood drops to 2 cm H 2 O. This valve can be positioned on the cover of an opening through which the patient is examined. This opening also allows the operators to clean the patient's face (e.g., if the patient frequently needs to expectorate) and to perform bronchial aspiration, which otherwise would require temporary removal of the hood.
Inspection of the thorax could be performed easily. Inspection of the infant abdomen sometimes required raising the "baby-body" without removing it. Heart and lung murmurs could be monitored at a high CPAP level. A nasogastric tube was provided to all children: Its exit from the helmet did not provoke any significant air leakage.
The institutional ethics committee approved the study, and detailed informed consent was provided by each patient's relatives. The investigation was conducted according to the Helsinki Declaration.
Study Design and Patient Selection. We conducted a single-center, prospective, clinical study of feasibility and safety involving pediatric patients with hypoxemic ARF who were admitted to the pediatric intensive care unit (PICU) of the Ospedali Riuniti of Bergamo (Italy) from February to December 2004.
The criterion for eligibility for helmet treatment was an oxygen saturation Ͻ92% while the patient was breathing oxygen through a Venturi face mask with an FIO 2 of 98%.
Children with one or more of the following problems were excluded: severe hemodynamic instability; encephalopathy; respiratory failure caused by neuromuscular disease; status asthmaticus; bronchopulmonary dysplasia; tracheostomy; recent oral, esophageal, gastric, or cyanotic cardiac surgery; and bowel occlusion.
The baseline ratio of PaO 2 /FIO 2 was calculated while the child was breathing 50% oxygen through the helmet with a CPAP of 0 cm H 2 O for 15 mins. A child was included in the study if the PaO 2 /FIO 2 ratio was Ͻ300 mm Hg.
The child was then submitted to a "CPAP test" at a low CPAP level (5 cm H 2 O) and at a high CPAP level (10 cm H 2 O); each test lasted 30 mins. After the test, a physician chose the CPAP level according to the CPAP test and a clinical assessment. The CPAP then continued for 2 hrs before a new clinical evaluation. Afterward, the CPAP was maintained until the child's oxygenation and clinical status improved.
If the child did not respond to the CPAP test, respiratory management was undertaken by the intensive care physician on duty. If endotracheal intubation was required, the helmet was easily removed and the child was promptly intubated.
The Pediatric Index of Mortality II score (23) was calculated at PICU admission, whereas organ failure (24) was assessed at the time of admission to the study.
Monitoring and Measurement. All children had continuous electrocardiography, oxygen saturation monitoring, and invasive blood pressure monitoring. Arterial gas exchange, respiratory rate, systolic blood pressure, and heart rate were registered after each CPAP increment (0, 5, 10 cm H 2 O) and after 2 hrs of CPAP.
A nursing chart was used to detect NIVrelated complications and the total hours and days of CPAP. The children's comfort was scored using the Children's and Infants' Postoperative Pain Scale (CHIPPS) (25) by the attending nurse. This scale (minimum score 0 and maximum score 10) was specifically designed for infants and young children and contains five categories of assessment: crying, facial expression, posture of the trunk, posture of the legs, and motor restlessness.
End Points and Definitions. The primary end point was the feasibility of CPAP with the modified helmet. Feasibility was defined according to the following criteria: a) absence of impairment of gas exchange with the helmet (impairment was defined as a PaO 2 /FIO 2 ratio of 10% or development of hypercapnia during the CPAP increment); b) absence of helmet CPAP-related complications (facial or other skin necrosis, gastric distension, conjunctivitis, epistaxis, loss of invasive devices); and c) tolerance of the helmet without signs of discomfort, defined as a CHIPPS score Ͻ4.
If one of the feasibility criteria was not met during the helmet CPAP, the physician stopped the treatment and chose a course of respiratory failure management according to his clinical judgment. A secondary end point was the improvement of gas exchange.
A positive response to the use of the helmet was defined as an improvement in the PaO 2 / FIO 2 ratio of 10% in the CPAP increment from 0 to 10 cm H 2 O. Gas exchange was evaluated 30 mins after the modification of the CPAP level. The "best CPAP" was defined as the CPAP level at which the highest PaO 2 /FIO 2 was obtained. Sustained improvement in gas exchange was defined as the ability to maintain improvement over the baseline PaO 2 /FIO 2 after 2 hrs of CPAP with the helmet.
Criteria for Endotracheal Intubation. Predetermined criteria for endotracheal intubation (7) were failure to maintain a PaO 2 Ͼ65 mm Hg with an FIO 2 Ͼ0.6; clinical signs of exhaustion (active contraction of the accessory muscles of respiration with paradoxical abdominal or thoracic motion); development of conditions necessitating endotracheal intubation to protect the airways from aspiration; and any hemodynamic instability.
Data Analysis. Values are expressed as mean Ϯ SD. We used one-way analysis of variance for repeated measurements to compare the three study steps: CPAP at 0 cm H 2 O, best CPAP, and after 2 hrs of CPAP. When a statistically significant effect was detected, post hoc comparisons were performed using the Bonferroni test to identify significant differences 
RESULTS

Characteristics of the Patients and
Etiology of Respiratory Failure. Fifteen children with acute hypoxemic respiratory failure met the enrollment criteria during the study period and were treated with helmet CPAP. Nine were Յ1 yr old. Ten of them were postextubation ARF, and nine had multiple organ failure. The population studied had a Pediatric Index of Mortality II score of 8.8 Ϯ 7.4 with a length of PICU stay of 10 Ϯ 4 days (including the time before and after CPAP). The baseline characteristics, comorbid conditions, and causes of respiratory failure are reported in Tables 1 and 2 .
Outcome Variable: Feasibility. No children failed the helmet-delivered CPAP because of agitation or any other clinical indication of patient discomfort. No children developed skin breakdown, conjunctivitis, gastric distension, epistaxis, loss of invasive devices, or pubic lesion during NIV with the helmet. No PICU fatalities were observed.
Two children developed exhaustion with hypercapnia and were intubated after a safe and quick removal of the helmet. They were not sedated and showed sustained improvement after 2 hrs of treatment, without impairment of PaCO 2 . They respectively required 3 and 7 days of additional mechanical ventilation.
Modified helmet CPAP was applied for a mean of 40 Ϯ 30 hrs and for a mean of 3 Ϯ 1.3 days. Sedation with low-dose midazolam (0.15 Ϯ 0.1 mg/kg/hr) was provided to four patients to improve their compliance to the device (CHIPPS score Ͻ4). The remaining patients received no sedation. One patient died of multiple organ failure related to acute hepatic failure several weeks after discharge from our PICU. No helmet-related complications were connected to this death.
Outcome Variable: Gas Exchange. Although not significant (p ϭ .17 vs. baseline), an increase of the PaO 2 /FIO 2 was observed at the best CPAP (Table 3 , Fig. 3 ).
Six children had improved PaO 2 /FIO 2 only at a low CPAP level (5 cm H 2 O) (Fig.  4A) ; four children had improved PaO 2 / FIO 2 only at a high CPAP level (10 cm H 2 O) (Fig. 4B) ; three children had improved PaO 2 /FIO 2 at low and high CPAP levels (Fig. 4C) ; and two patients did not respond to the CPAP test (Fig. 4D) . A sustained significant improvement of PaO 2 /FIO 2 (p ϭ .008 vs. baseline) was observed after 2 hrs of CPAP (Table 3, Fig.  3 ). CPAP chosen by the physician after the CPAP test was 6.8 Ϯ 2 cm H 2 O.
CPAP increments did not significantly alter PaCO 2 , respiratory rate, heart rate, or systolic blood pressure (Table 3) .
DISCUSSION
During the last 15 yrs, several studies have reported a promising clinical application of noninvasive CPAP in patients with hypoxemic ARF of various etiologies (4 -6) .
Having few data on the utility and feasibility of CPAP for the treatment of hypoxemic respiratory failure in infants (14), we conducted a study to test the feasibility of helmet-delivered CPAP in this population. Our data confirmed previous reports of the feasibility of helmet use in adults (6, 21, 22) and in pediatric (9) and preterm infants population (19, 20) . In comparison with previous pediatric and preterm infants reports (9, 19, 20) , our study showed that the helmet treatment is viable in infants and preschool children with ARF and multiple organ failure, with some technical modifications (i.e., various sizes of helmet and use of the baby-body).
One key to obtaining adequate noninvasive respiratory support is the patientequipment interface: Nasal and facial masks are associated with skin breakdown, conjunctivitis, gastric distension, and epistaxis (3, 14, 17) . In our experience with the helmet, neither skin abrasions nor other cutaneous lesions were observed. Patient tolerance of CPAP also deserves attention, because sedation is sometimes administered to adults and children (14, 17) to improve their cooperation. In our study, mild sedation was implemented only in four cases, using PIM, Pediatric Index of Mortality; ARF, acute respiratory failure; OLT, orthotopic liver transplantation; rs, respiratory; hm, hematologic; hp, hepatic; RSV, respiratory sincizial virus; AVC, atrioventricular channel; EA, esophageal atresia; ALL, accute lymphocytic leukemia. low-dose midazolam (0.15 Ϯ 0.1 mg/kg/ hr) to reduce the CHIPPS score to a value Ͻ4 (the score that defines helmet tolerance). In all the remaining cases, helmet use was well tolerated without sedative drugs. The transparency of the device allows the children to see and interact with relatives and probably contributes to improved tolerance. A third advantage of the helmet is related to the "baby-body"; it reduces air leakage and permits frequent changes of the wearer's position. The mean time spent by a nurse to prepare the CPAP system and install the helmet on the head of the child was 5.4 mins. A second nurse was needed only during installation. After installation of the helmet, the nursing management of respiratory failure (variable detection, postural changes, and gas flow control) was the same as it was during oxygen therapy. Medical work was not affected by treatment with the helmet because management of the device was charged entirely to the nursing staff. Another improvement is the use of the "baby-body," which avoids armpit-lesion formation provoked by the use of the armpit braces that have been proposed for fixing helmets to adults (22) . The closed system of the helmet allows us to maintain a high degree of humidification, which could be remarkable on reduction of epistaxis, dry nostrils, and secretions (14) , and still see the patient. No episodes of infection or fever related to the high degree of humidification were observed.
Some additional information can be drawn from this study. Although not significant, PaO 2 /FIO 2 increased over the baseline values at best CPAP. Two children did not have improved PaO 2 /FIO 2 after the CPAP test (Fig. 4D) but after 2 hrs of continuous CPAP only. Their helmet treatment was continued in light of observations that early CPAP results in decreased rates of intubation and other complications in patients with postoperative hypoxemia (6) .
PaCO 2 at best CPAP was not significantly different from the baseline, and this may leave some doubts (26) about increasing the end-expiratory lung volume with CPAP. Significant sustained improvement of PaO 2 /FIO 2 after 2 hrs of CPAP may support the hypothesis that CPAP maintained an increase in endexpiratory lung volume with a decrease of ventilation/perfusion ratio.
The CPAP test was performed at three levels of CPAP (0, 5, and 10 cm H 2 O) to identify the best oxygenation response. We did not use CPAP at 15 cm H 2 O because significant air leakage occurs at this level. All six children who had improved PaO 2 / FIO 2 at low CPAP levels (Fig. 4A) were Յ1 yr old. Three of them were Ͻ5 months and weighed Ͻ6 kg. The CPAP test adequately and quickly revealed the effect of the CPAP on oxygenation, allowing the clinicians to use the lowest effective intra-airway pressure in the infant to avoid excessive alveolar overdistention and hemodynamic derangement.
Two children were intubated due to respiratory fatigue after several hours of CPAP; they did not receive any sedative drugs and showed sustained improvement of PaO 2 /FIO 2 . Their deterioration was attributed to the derangement of metabolic homeostasis (metabolic acidosis and hepatic failure) with the consequent development of respiratory fatigue.
Although a high inspiratory flow was used, we cannot exclude some influence on PaCO 2 due to rebreathing, as suggested by another study (21) ; respiratory rate was not significantly different at different CPAP levels. The equivalent decibel A level generated from high inspiratory flows into the helmet was 71.2; it decreased to 66.3 with a Gibeck filter inserted at the inspiratory port. The children usually fell asleep within the helmet despite high inspiratory flows.
This feasibility study has several limitations: the number and variety of patients studied (46% of them were ARF postextubation after orthotopic liver transplantation); the low number of monitored, relevant hemodynamic variables such as venous saturation of oxygen; and the absence of an evaluation of CO 2 rebreathing and of adequate gas humidification by the hygrometer. The only type of NIV tested was CPAP, which is the simplest form of NIV support (3): For this reason the results described are limited to this CPAP system.
CONCLUSIONS
The modified helmet seems to be a suitable device for delivery of CPAP to infants and preschool children with hypoxemic ARF. It seems to be well tolerated and without major complications. A randomized trial is needed to demonstrate the real advantages of this new device with respect to conventional techniques.
